Abeona Therapeutics Inc. (ABEO) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Abeona Therapeutics Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:01.472 submissions, 00:00:01.472 -- 00:00:04.094 we resumed biopsy collection in November 2025. 00:00:04.094 -- 00:00:05.576 We 00:00:05.576 -- 00:00:09.059 now anticipate patient treatment starting in the fourth quarter of 2025. 00:00:09.059 -- 00:00:15.462 I will now hand the call over to Chief Commercial Officer Madhav Vasadavanthavada 00:00:15.984 -- 00:00:18.306 to discuss our commercial launch progress. 00:00:18.306 -- 00:00:20.306 Madhav? 00:00:20.708 -- 00:00:22.490 Thanks, Brian. 00:00:22.490 -- 00:00:24.770 Hello, everyone. 00:00:24.792 -- 00:00:30.946 Our launch momentum continues to accelerate on multiple fronts. 00:00:30.946 -- 00:00:34.852 patient demand continues to build, 00:00:34.852 -- 00:00:39.939 our relationships and trust with qualified treatment centers have grown 00:00:39.939 -- 00:00:42.002 stronger, and 00:00:42.002 -- 00:00:48.889 patient access to ZivaSkin across all payer types has continued to broaden. 00:00:49.693 -- 00:00:55.081 On our second quarter call, we mentioned more than a dozen initial patients were identified 00:00:55.081 -- 00:00:59.427 at the first two qualified treatment centers. 00:00:59.427 -- 00:01:05.051 Of these patients, We have already received ZivaSkin product order forms, 00:01:05.051 -- 00:01:09.275 or ZPOFs, for 12 patients. 00:01:09.839 -- 00:01:14.888 A ZPOF is an informed consent generated by the QTC physician 00:01:14.888 -- 00:01:18.695 after the patient has been consulted, 00:01:18.695 -- 00:01:24.085 a treatment decision has been made, and the patient and their families have 00:01:24.085 -- 00:01:26.906 decided to move forward. 00:01:27.680 -- 00:01:32.887 Insurance prior authorizations have been obtained for several patients already, 00:01:32.887 -- 00:01:38.153 and we expect...